Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5599082 | 0.73 | SMN1; SMN2 (0.46) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL5489748 | 0.71 | SMN1; SMN2 (0.44) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL4253446 | 0.71 | SMN1; SMN2 (0.53) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL20936054 | 0.71 | SMN1; SMN2 (0.44) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL15329364 | 0.67 | SMN1; SMN2 (0.41) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL11134639 | 0.67 | SMN1; SMN2 (0.41) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL12499138 | 0.67 | SMN1; SMN2 (0.44) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL14564596 | 0.66 | SMN1; SMN2 (0.40) | SMN1; SMN2GLAKMT2AL3MBTL1 | |
| SCHEMBL20170045 | 0.66 | SMN1; SMN2 (0.43) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL5599103 | 0.66 | KMT2A (0.49) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369716-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-12-02 | — | — | US | disclosed |
| US-11123348-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2021-09-21 | — | — | US | disclosed |
| US-20200179391-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2020-06-11 | — | — | US | disclosed |
| US-10596175-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2020-03-24 | — | — | US | disclosed |
| US-20190000852-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2019-01-03 | — | — | US | disclosed |
| US-9700559-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2017-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000852-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | SMN1; SMN2 705/4885GLA 1449/4885KMT2A 2041/4885 |
| US-11123348-B2 | Compounds and compositions for the treatment of parasitic diseases | TYR, TBCA, MAPT | SMN1; SMN2 705/4885GLA 1449/4885KMT2A 2041/4885 |
| US-10596175-B2 | Compounds and compositions for the treatment of parasitic diseases | TYR, TBCA, MAPT | SMN1; SMN2 705/4885GLA 1449/4885KMT2A 2041/4885 |
| US-20210369716-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | SMN1; SMN2 705/4885GLA 1449/4885KMT2A 2041/4885 |
| US-20200179391-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | SMN1; SMN2 705/4885GLA 1449/4885KMT2A 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.